^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CBP-1008

    i
    Other names: CBP-1008
    Company:
    Coherent Biopharma
    Drug class:
    Microtubule inhibitor, Folate receptor 1 inhibitor, TRPV6 inhibitor
    Related drugs:
    3ms
    A Study of CBP-1008 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=143, Recruiting, Coherent Biopharma (Suzhou) Co., Ltd. | Phase classification: P1a/1b --> P1 | Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    CBP-1008
    over1year
    Bispecific-XDC: Novel First-in-Class Cancer Therapies From Concept to Clinical (ADC-USA 2023)
    Describing CBP-1008: a FR/ TRPV6 targeted drug conjugate in Phase II pivotal studies of advanced ovarian cancer treatment; Exploring CBP-1018: a FR/ PSMA targeted drug conjugate in Phase Ib for prostate cancer therapy; Highlighting CBP-1019: TOP1i payload drug conjugate for unmet medical needs
    Clinical
    |
    TRPV6 (Transient Receptor Potential Cation Channel Subfamily V Member 6)
    |
    CBP-1008 • CBP-1018 • CBP-1019
    over2years
    CBP-1008 shows excellent efficacy and desirable drug safety profile in preclinical models (AACR 2022)
    Within the FRα+/TRPV6+ tumors, tumor growth inhibition well correlates with IHC score of FRα (R2=0.89).It is indicated that clinical trials in selected indications using biomarkers assay to screening patients will expedite the clinical development of CBP-1008. Initial clinical response has been observed in our Phase I trial.
    Preclinical
    |
    FOLR1 ( Folate receptor alpha )
    |
    CBP-1008